| Drug General Information |
| Drug ID |
D0EV6B
|
| Former ID |
DNC002792
|
| Drug Name |
N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H27N5O
|
| Canonical SMILES |
C1C2CC3CC1CC(C2)(C3)NC(=O)NCC4=CC=C(C=C4)N=C(N)N
|
| InChI |
1S/C19H27N5O/c20-17(21)23-16-3-1-12(2-4-16)11-22-18(25)24-19-8-13-5-14(9-19)7-15(6-13)10-19/h1-4,13-15H,5-11H2,(H4,20,21,23)(H2,22,24,25)
|
| InChIKey |
YQPLKJCBEOVDBS-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
838329, 4822239, 7885763, 14851548, 29223385, 32964195, 46391803, 46507016, 46516433, 50750500, 57322227, 104305960, 126407836, 137220307, 139121217, 139121220, 139634360, 139634363, 142869164, 160966870, 163039167, 230268015, 239503636, 244497849, 246144881, 248575246
|
| Target and Pathway |
| Target(s) |
Urokinase-type plasminogen activator |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
Complement and coagulation cascades
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
PANTHER Pathway
|
Blood coagulation
|
|
Plasminogen activating cascade
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Beta1 integrin cell surface interactions
|
|
E2F transcription factor network
|
|
Beta3 integrin cell surface interactions
|
|
Osteopontin-mediated events
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
amb2 Integrin signaling
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
Beta2 integrin cell surface interactions
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
|
FGF signaling pathway
|
|
Reactome
|
Dissolution of Fibrin Clot
|
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
|
Senescence and Autophagy in Cancer
|
|
Complement and Coagulation Cascades
|
|
Endochondral Ossification
|
|
Wnt Signaling Pathway
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Blood Clotting Cascade
|
|
Dissolution of Fibrin Clot
|
|
Osteopontin Signaling
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
